NASDAQ · Biotechnology

NAMS (NAMS) Stock

$27.98 -7.41% NASDAQ: NAMS Healthcare

Valuation

MetricValue
Price$27.98
Market Cap$3.27B
P/E Ratio-19.27
P/B Ratio5.77
P/S Ratio174.70
EPS (TTM)$-1.75
52-Week High$42.20
52-Week Low$17.63
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-29.87%
ROA-26.53%
ROCE-33.09%
Gross Margin-978.26%
Operating Margin-982.61%
Net Margin-9.43%
Debt/Equity0.00
Current Ratio7.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$103.0M$14.0M$46.0M$23.0M
Operating Profit$-35.0M$-4.0M$-183.0M$-176.0M$-226.0M
Net Profit$-42.0M$-23.0M$-177.0M$-242.0M$-204.0M
EPS$-3.34$-1.19$-2.15$-2.56$-1.75
Op Margin—-3.5%-1298.6%-386.9%-1002.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$68.0M$478.0M$347.0M$865.0M$769.0M
Total Liabilities$11.0M$48.0M$59.0M$107.0M$86.0M
Cash$60.0M$468.0M$340.0M$772.0M$490.0M
Borrowings$0$0$0$0$0

Latest News

Attovia Therapeutics Appoints John W. Smither to Board of Directors GlobeNewswire · Jul 15, 2026 Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma CNW Group · Jul 7, 2026 NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 GlobeNewswire · Jul 1, 2026 NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says MT Newswires · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-30.0M$11.0M$-141.0M$-159.0M$-148.0M
Investing Cash Flow$0$0$0$-64.0M$-175.0M
Financing Cash Flow$0$-6.0M$0$14.0M$0
Net Cash Flow$50.0M$408.0M$-127.0M$431.0M$-280.0M
Free Cash Flow$-30.0M$10.0M$-141.0M$-159.0M$-148.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-3.61%
Quick Ratio9.76
Interest Coverage—
Return 1Y38.90%
Return 3Y171.06%
Return 5Y228.35%

Ownership

Insiders Held0.91%
Institutions Held106.63%
Institutions Float Held107.61%
Institutional HolderSharesReport Date
Frazier Life Sciences Management, L.P. 16,943,7742026-03-31
Capital World Investors11,109,0342026-03-31
RA Capital Management, L.P.9,550,1912026-03-31
FCPM III Services B.V.9,198,9002026-03-31
FMR, LLC8,765,8112026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACLXArcellx, Inc. $115.07 +0.02% -28.27 $6.73B 0.00%
AKROAkero Therapeutics, Inc. $54.65 +0.00% -19.87 $4.50B 0.00%
CGON $72.17 -1.84% -26.72 $6.37B 0.00%
CRNX $83.81 -0.09% -8.57 $8.87B 0.00%
IMVT $39.24 +1.91% -11.09 $8.06B 0.00%

About NAMS

NAMS stock trades at $27.98 with a market capitalization of $3.27B. The stock is valued at a price-to-earnings (P/E) ratio of -19.27, price-to-book of 5.77, price-to-sales of 174.70. Over the past 52 weeks the stock has ranged between $17.63 and $42.20, and currently trades 33.7% below its 52-week high.

On profitability, NAMS generates a return on equity (ROE) of -29.87%, return on capital employed of -33.09%, an operating margin of -982.61%, a net profit margin of -9.43%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides